Biosynthetic Technologies
About Biosynthetic Technologies
Biosynthetic Technologies is a company based in Indianapolis (United States) founded in 2012 was acquired by Calumet Specialty Products Partners in April 2018. Biosynthetic Technologies has raised $52.24 million across 8 funding rounds from investors including bp, Monsanto and The Heritage Group. Biosynthetic Technologies has completed 1 acquisition, including Innoleo. Biosynthetic Technologies offers products and services including Estolides, BioEstolides, and Industrial Lubricants. Biosynthetic Technologies operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Indianapolis, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biosynthetic Technologies, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$52.24 M (USD)
in 8 rounds
-
Latest Funding Round
$9.5 M (USD), Series A
May 07, 2019
-
Investors
bp
& 5 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Calumet Specialty Products Partners
(Apr 09, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biosynthetic Technologies
Biosynthetic Technologies offers a comprehensive portfolio of products and services, including Estolides, BioEstolides, and Industrial Lubricants.
Sustainable compounds from bio-derived fatty acids for lubricant formulations.
Biodegradable oils for skincare and cosmetics applications.
High-performance oils for gear and hydraulic systems.
People of Biosynthetic Technologies
Unlock access to complete
Funding Insights of Biosynthetic Technologies
Biosynthetic Technologies has successfully raised a total of $52.24M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $9.5 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biosynthetic Technologies
Biosynthetic Technologies has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include bp, Monsanto and The Heritage Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A family-owned business managing diverse industrial and environmental companies.
|
Locked | Locked | Locked | |
|
Corporate venture capital investments are made by Evonik.
|
Locked | Locked | Locked | |
|
bp is recognized as a global energy company.
|
Locked | Locked | Locked |
Investor details for Biosynthetic Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosynthetic Technologies
Biosynthetic Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Innoleo.
Investment portfolio details for Biosynthetic Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Supplier & distributor of castor oil and derivatives of castor oil
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Biosynthetic Technologies
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biosynthetic Technologies
Detailed financials for Biosynthetic Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosynthetic Technologies Comparisons
Peer comparison for Biosynthetic Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biosynthetic Technologies
Biosynthetic Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Biosynthetic Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosynthetic Technologies
Complete news archive for Biosynthetic Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosynthetic Technologies
Biosynthetic Technologies was founded in 2012.
Biosynthetic Technologies is headquartered in Indianapolis, United States. It is registered at Indianapolis, Indiana, United States.
Mark Miller is the current CEO of Biosynthetic Technologies.
Biosynthetic Technologies is a funded company, having raised a total of $52.24M across 8 funding rounds to date.
Manufacturer of bio-based green oils. They produce synthetic oils, called estolides, from organic fatty acids found in various bio-derived oils. These are bio-degradable non-toxic and can be used as the primary base oil of a lubricant formulation, a component of a base oil co-blend, or as an additive. These oils have applications in many industries, such as cosmetic, chemicals, food-grade lubricants, car motor oil, and marine lubricant.
Biosynthetic Technologies's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Biosynthetic Technologies offers Estolides, BioEstolides, and Industrial Lubricants.
Biosynthetic Technologies has made 1 acquisition, including Innoleo.
Biosynthetic Technologies has 6 investors. Key investors include bp, Monsanto, The Heritage Group, Evonik Venture Capital, and OSTI.GOV.